- Antitumor effects and enhanced survival (median survival of 27 and 37 days in CD19-CAR and CD44v6-CAR treated groups of mice)- CD44v6-CAR T cells inhibited tumor growth and prolonged overall survival (median survival of 21.5 and 37 days in CD19-CAR and CD44v6-CAR treated groups of mice). The gene discussed is CD19; the disease is neoplasm.